The phase II PULSE trial (NCT03774901) is evaluating maintenance avelumab, an anti-PD-L1 antibody, in patients with metastatic PSCC who have not progressed following first-line platinum-based polychemotherapy. Here, CD274 is linked to squamous cell carcinoma of penis.